Myeloprotection with drug-resistance genes Journal Article
| Authors: | Banerjee, D.; Bertino, J. R. |
| Article Title: | Myeloprotection with drug-resistance genes |
| Abstract: | One of the many applications of gene transfer for cancer gene therapy is the transfer of drug-resistance genes into bone-marrow stem cells for myeloprotection. Protection of the hosts' bone marrow should allow for dose escalation that may be useful for eradicating minimal residual disease in a post-transplant situation. A number of drug resistance genes, whose products include mutant forms of enzymes that confer resistance to chemotherapeutic drugs, are discussed. Advances in hematopoietic stem cell isolation and ex vivo manipulation has kept pace with improvements in retroviral vector technology to make hematopoietic: stem cell transduction a distinct reality. Clinical trials, which have established that the approach is safe, are now being designed to address more therapeutically relevant issues. |
| Keywords: | controlled study; clinical trial; review; cisplatin; fluorouracil; nonhuman; antineoplastic agents; gemcitabine; paclitaxel; cytarabine; methotrexate; temozolomide; antineoplastic agent; sensitivity and specificity; mutant protein; neoplasms; carboplatin; protein bcl 2; unindexed drug; controlled clinical trial; bone marrow; bone marrow suppression; etoposide; cyclophosphamide; nucleoside analog; hematopoietic stem cell transplantation; drug resistance; biotechnology; carmustine; chlormethine; viral gene delivery system; genetic vectors; cytidine deaminase; minimal residual disease; cell isolation; glutathione transferase; gene therapy; retrovirus vector; hematopoietic stem cells; vinca alkaloid; hematopoietic stem cell; methylated dna protein cysteine methyltransferase; anthracycline; dihydrofolate reductase; thymidylate synthase; bone marrow transplantation; cell protection; host cell; complementary dna; bone marrow toxicity; gene transfer techniques; multidrug resistance protein 1; nucleosidase; raltitrexed; eradication therapy; trimetrexate; viral gene therapy; nolatrexed; clinical trials, phase ii; cancer; humans; human; male; female; priority journal |
| Journal Title: | Lancet Oncology |
| Volume: | 3 |
| Issue: | 3 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2002-03-01 |
| Start Page: | 154 |
| End Page: | 158 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(02)00678-2 |
| PUBMED: | 11902501 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 14 November 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work